Pamela Camp
Nurse Practitioner · Chattanooga, TNNPI 1689920787
Payments from drug & device makers
Across 256 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$930
- Sanofi$431
- Regeneron Healthcare Solutions, Inc.$300
- Grifols USA, LLC$261
- Biocryst US Sales Co., LLC$160
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,47098%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,811 |
| GSK | 61 | $930 |
| Sanofi | 19 | $431 |
| Regeneron Healthcare Solutions, Inc. | 13 | $300 |
| Grifols USA, LLC | 14 | $261 |
| Biocryst US Sales Co., LLC | 8 | $160 |
| Genentech USA, Inc. | 8 | $149 |
| Pfizer | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $137 |
| Incyte Corporation | 2 | $137 |
| Amgen | 6 | $129 |
| Novartis | 6 | $127 |
| Optinose US, Inc. | 7 | $122 |
| Kaleo, Inc. | 6 | $105 |
| Mylan Specialty L.p. | 4 | $94 |
| Boehringer Ingelheim | 4 | $76 |
| CSL Behring | 3 | $73 |
| Sanofi-aventis U.S. LLC | 1 | $70 |
| AbbVie | 3 | $62 |
| Pharming Healthcare, Inc. | 2 | $49 |
| ADMA Biomanufacturing LLC | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $18 |
| LEO Pharma Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Alk-abello, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,563 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 23 | $98,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $76,826 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $51,299 |
| Epinephrine | 54 | $10,311 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,394 |
| DuleraMometasone/Formoterol | 21 | $7,774 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,232 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $6,172 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $4,638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 102 | $2,991 |
| Mometasone Furoate | 26 | $2,720 |
| Montelukast Sodium | 202 | $2,360 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,277 |
| Levocetirizine Dihydrochloride | 95 | $1,057 |
| Azelastine Hcl | 31 | $1,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere | $1,811 | $149,65699 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $930 | $87,497121 claims |
| MerckDulera | $16 | $7,77421 claims |
| Boehringer IngelheimSpiriva Respimat | $76 | $7,23214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.